PTC Therapeutics, Inc. (PTCT)
Price:
64.48 USD
( + 0.57 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Incyte Corporation
VALUE SCORE:
10
2nd position
Harmony Biosciences Holdings, Inc.
VALUE SCORE:
12
The best
Agios Pharmaceuticals, Inc.
VALUE SCORE:
12
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
No data to display
DESCRIPTION
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
NEWS
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
prnewswire.com
2025-10-01 16:30:00WARREN, N.J. , Oct. 1, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Sept.
PTC Therapeutics, Inc. (PTCT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
seekingalpha.com
2025-09-08 12:44:24PTC Therapeutics, Inc. (NASDAQ:PTCT ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 9:15 AM EDT Company Participants Matthew Klein - CEO & Director Pierre Gravier - Chief Financial Officer Conference Call Participants Judah Frommer - Morgan Stanley, Research Division Presentation Judah Frommer Equity Analyst All right. Welcome, everyone, to this session of the Morgan Stanley Global Healthcare Conference.
Here's Why Shares in PTC Therapeutics Soared This Week
fool.com
2025-09-05 08:35:04Shares in PTC Therapeutics (PTCT 4.43%) surged by 17.5% in the week to Friday morning, as the market digested management's upbeat presentation at the Cantor Global Healthcare Conference on Wednesday.
PTC Therapeutics Stock Is Stuck In A Multi-Year Slump
benzinga.com
2025-08-21 10:00:45PTC Therapeutics PTCT is currently in the final 18th phase of its Adhishthana cycle on the weekly chart, and the outlook remains bleak. Signals point to prolonged underperformance, with weakness likely to last through 2030.
PTC Therapeutics to Participate at Upcoming Investor Conferences
prnewswire.com
2025-08-21 08:00:00WARREN, N.J. , Aug. 21, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: Cantor Global Healthcare Conference 2025 Wednesday, Sept.
PTC Therapeutics: HD Treatment Advancement Continues With Q4 2025 Catalyst
seekingalpha.com
2025-08-20 15:53:02Company is positioned for growth with SEPHIENCE, approved for PKU in the US and Europe, and pending decisions in Japan and Brazil. Votoplam (PTC518) for Huntington's Disease shows promising phase 2 results; a key FDA meeting in Q4 2025 could enable Accelerated Approval and set a phase 3 trial design. Strong partnership with Novartis provides financial strength and development support for votoplam for treatment of HD patients, with up to $1.9 billion in milestone payments possible.
PTC Therapeutics Faces FDA Rejection On Rare Disease Treatment Over Efficacy Concerns
benzinga.com
2025-08-19 11:20:22The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) on Tuesday related to PTC Therapeutics, Inc.‘s PTCT New Drug Application (NDA) for vatiquinone for Friedreich's ataxia.
US FDA declines to approve PTC Therapeutics' rare genetic disorder drug
reuters.com
2025-08-19 08:06:43The U.S. Food and Drug Administration has declined to approve PTC Therapeutics' drug to treat a rare genetic disorder that causes progressive damage to the nervous system, the company said on Tuesday, delaying a potential treatment for patients with limited treatment options.
PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA
prnewswire.com
2025-08-19 08:00:00WARREN, N.J. , Aug. 19, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) related to the New Drug Application (NDA) for vatiquinone for the treatment of children and adults living with Friedreich's ataxia.
PTC Therapeutics, Inc. (PTCT) Q2 2025 Earnings Call Transcript
seekingalpha.com
2025-08-08 15:19:14PTC Therapeutics, Inc. (NASDAQ:PTCT ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Ellen Cavaleri - Corporate Participant Eric Pauwels - Chief Business Officer Jarwei Fang - Corporate Participant Matthew B. Klein - CEO & Director Pierre Gravier - Chief Financial Officer Conference Call Participants Dingding Shi - Jefferies LLC, Research Division Huidong Wang - Barclays Bank PLC, Research Division Jenny Leigh Gonzalez-Armenta - Leerink Partners LLC, Research Division John Peyton Bohnsack - TD Cowen, Research Division Joon So Lee - Truist Securities, Inc., Research Division Judah C.
PTC Therapeutics (PTCT) Reports Q2 Earnings: What Key Metrics Have to Say
zacks.com
2025-08-07 19:01:26The headline numbers for PTC Therapeutics (PTCT) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
PTCT Earnings Beat but Sales Drop 4%
fool.com
2025-08-07 18:38:35PTCT Earnings Beat but Sales Drop 4%
PTC Therapeutics (PTCT) Reports Q2 Loss, Beats Revenue Estimates
zacks.com
2025-08-07 18:26:11PTC Therapeutics (PTCT) came out with a quarterly loss of $0.83 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to a loss of $1.16 per share a year ago.
No data to display
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
prnewswire.com
2025-10-01 16:30:00WARREN, N.J. , Oct. 1, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Sept.
PTC Therapeutics, Inc. (PTCT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
seekingalpha.com
2025-09-08 12:44:24PTC Therapeutics, Inc. (NASDAQ:PTCT ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 9:15 AM EDT Company Participants Matthew Klein - CEO & Director Pierre Gravier - Chief Financial Officer Conference Call Participants Judah Frommer - Morgan Stanley, Research Division Presentation Judah Frommer Equity Analyst All right. Welcome, everyone, to this session of the Morgan Stanley Global Healthcare Conference.
Here's Why Shares in PTC Therapeutics Soared This Week
fool.com
2025-09-05 08:35:04Shares in PTC Therapeutics (PTCT 4.43%) surged by 17.5% in the week to Friday morning, as the market digested management's upbeat presentation at the Cantor Global Healthcare Conference on Wednesday.
PTC Therapeutics Stock Is Stuck In A Multi-Year Slump
benzinga.com
2025-08-21 10:00:45PTC Therapeutics PTCT is currently in the final 18th phase of its Adhishthana cycle on the weekly chart, and the outlook remains bleak. Signals point to prolonged underperformance, with weakness likely to last through 2030.
PTC Therapeutics to Participate at Upcoming Investor Conferences
prnewswire.com
2025-08-21 08:00:00WARREN, N.J. , Aug. 21, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: Cantor Global Healthcare Conference 2025 Wednesday, Sept.
PTC Therapeutics: HD Treatment Advancement Continues With Q4 2025 Catalyst
seekingalpha.com
2025-08-20 15:53:02Company is positioned for growth with SEPHIENCE, approved for PKU in the US and Europe, and pending decisions in Japan and Brazil. Votoplam (PTC518) for Huntington's Disease shows promising phase 2 results; a key FDA meeting in Q4 2025 could enable Accelerated Approval and set a phase 3 trial design. Strong partnership with Novartis provides financial strength and development support for votoplam for treatment of HD patients, with up to $1.9 billion in milestone payments possible.
PTC Therapeutics Faces FDA Rejection On Rare Disease Treatment Over Efficacy Concerns
benzinga.com
2025-08-19 11:20:22The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) on Tuesday related to PTC Therapeutics, Inc.‘s PTCT New Drug Application (NDA) for vatiquinone for Friedreich's ataxia.
US FDA declines to approve PTC Therapeutics' rare genetic disorder drug
reuters.com
2025-08-19 08:06:43The U.S. Food and Drug Administration has declined to approve PTC Therapeutics' drug to treat a rare genetic disorder that causes progressive damage to the nervous system, the company said on Tuesday, delaying a potential treatment for patients with limited treatment options.
PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA
prnewswire.com
2025-08-19 08:00:00WARREN, N.J. , Aug. 19, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) related to the New Drug Application (NDA) for vatiquinone for the treatment of children and adults living with Friedreich's ataxia.
PTC Therapeutics, Inc. (PTCT) Q2 2025 Earnings Call Transcript
seekingalpha.com
2025-08-08 15:19:14PTC Therapeutics, Inc. (NASDAQ:PTCT ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Ellen Cavaleri - Corporate Participant Eric Pauwels - Chief Business Officer Jarwei Fang - Corporate Participant Matthew B. Klein - CEO & Director Pierre Gravier - Chief Financial Officer Conference Call Participants Dingding Shi - Jefferies LLC, Research Division Huidong Wang - Barclays Bank PLC, Research Division Jenny Leigh Gonzalez-Armenta - Leerink Partners LLC, Research Division John Peyton Bohnsack - TD Cowen, Research Division Joon So Lee - Truist Securities, Inc., Research Division Judah C.
PTC Therapeutics (PTCT) Reports Q2 Earnings: What Key Metrics Have to Say
zacks.com
2025-08-07 19:01:26The headline numbers for PTC Therapeutics (PTCT) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
PTCT Earnings Beat but Sales Drop 4%
fool.com
2025-08-07 18:38:35PTCT Earnings Beat but Sales Drop 4%
PTC Therapeutics (PTCT) Reports Q2 Loss, Beats Revenue Estimates
zacks.com
2025-08-07 18:26:11PTC Therapeutics (PTCT) came out with a quarterly loss of $0.83 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to a loss of $1.16 per share a year ago.